Combination vaccine

Abstract

The disclosure relates to a composition comprising two or more immunogenic staphylococcal polypeptides and a multivalent vaccine composition comprising the immunogenic staphylococcal polypeptides.

What is claimed is: 
     
         1 . A composition, comprising two or more different nucleic acid molecules each encoding an immunogenic staphylococcal extracellular domain polypeptide, wherein the nucleic acid molecules are selected from:
 (i) a nucleic acid molecule comprising or consisting of a nucleotide sequence as represented in SEQ ID NO.:7;   (ii) a nucleic acid molecule comprising or consisting of a nucleotide sequence as represented in SEQ ID NO.:8;   (iii) a nucleic acid molecule comprising or consisting of a nucleotide sequence as represented in SEQ ID NO.:9;   (iv) a nucleic acid molecule comprising or consisting of a nucleotide sequence as represented in SEQ ID NO.:10;   (v) any one of the nucleic acids of (i) to (iv), wherein the nucleotide sequence is degenerate as a result of the genetic code, provided that the degenerate nucleotide sequence encodes the same staphylococcal immunogenic extracellular domain polypeptide as the nucleic acid molecules of (i) to (iv), respectively;   (vi) any one of the nucleic acid molecules of (i) to (iv), wherein the nucleic acid molecule comprises or consists of a nucleotide sequence having at least 90% identity to the nucleotide sequence of the nucleic acid molecules of (i) to (iv), respectively; and   (vii) a nucleic acid molecule, wherein the complementary strand of the nucleic acid molecule hybridizes under stringent hybridization conditions to the nucleotide sequence as represented in SEQ ID NO.:7, 8, 9 or 10, and wherein the nucleic acid molecule encodes an immunogenic staphylococcal extracellular domain polypeptide.   
     
     
         2 . An immunogenic composition, comprising:
 (i) an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:21, and an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:23;   (ii) an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:21, and an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:24;   (iii) an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:22, and an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:23;   (iv) an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:22, and an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:24;   (v) an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:23, and an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:24;   (vi) an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:21, an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:23, and an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:24;   (vii) an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:22, an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:23, and an immunogenic extracellular domain polypeptide, or immunogenic fragment thereof, comprising or consisting of the amino acid sequence as represented in SEQ ID NO.:24; or   (viii) any one of the compositions of (i) to (vii), wherein the immunogenic extracellular domain polypeptide or immunogenic fragment thereof is an immunogenic extracellular domain polypeptide variant having at least 90% identity to the amino acid sequence presented in the corresponding SEQ ID NO.   
     
     
         3 . The immunogenic composition according to  claim 2 , comprising:
 (i) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:21, or an antigenic fragment thereof; and   (ii) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:23, or an antigenic fragment thereof.   
     
     
         4 . The immunogenic composition according to  claim 2 , comprising:
 (i) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:21, or an antigenic fragment thereof; and   (ii) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:24, or an antigenic fragment thereof.   
     
     
         5 . The immunogenic composition according to  claim 2 , comprising:
 (i) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:21, or an antigenic fragment thereof; and   (ii) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:23, or an antigenic fragment thereof, and   (iii) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:24, or an antigenic fragment thereof.   
     
     
         6 . The immunogenic composition according to  claim 2 , comprising
 (i) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:22, or an antigenic fragment thereof; and   (ii) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:23, or an antigenic fragment thereof.   
     
     
         7 . The immunogenic composition according to  claim 2 , comprising:
 (i) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:22, or an antigenic fragment thereof; and   (ii) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:24, or an antigenic fragment thereof.   
     
     
         8 . The immunogenic composition according to  claim 2 , comprising:
 (i) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:22, or an antigenic fragment thereof; and   (ii) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:23, or an antigenic fragment thereof, and   (iii) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:24, or an antigenic fragment thereof.   
     
     
         9 . The immunogenic composition according to  claim 2 , comprising:
 (i) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:23, or an antigenic fragment thereof; and   (ii) an immunogenic extracellular domain polypeptide comprising SEQ ID NO.:24, or an antigenic fragment thereof.   
     
     
         10 . The immunogenic composition according to  claim 2 , further comprising a carrier, an adjuvant or both. 
     
     
         11 . The immunogenic composition according to  claim 2 , wherein the composition is a vaccine. 
     
     
         12 . The immunogenic composition according to  claim 11 , wherein the vaccine is adapted for administration as a nasal spray. 
     
     
         13 . The immunogenic composition according to  claim 12 , wherein the vaccine is provided in an inhaler and delivered as an aerosol. 
     
     
         14 . A method of treating a staphylococcal infection in an animal subject, comprising administering an effective amount of an immunogenic composition according to  claim 1 . 
     
     
         15 . The method of  claim 14 , wherein the immunogenic composition further comprises a carrier, an adjuvant or both. 
     
     
         16 . The method of  claim 15 , wherein the adjuvant is aluminium phosphate. 
     
     
         17 . The method of  claim 14 , wherein the immunogenic composition further comprises an adjuvant and the composition is formulated as a gel. 
     
     
         18 . The immunogenic composition according to  claim 14 , wherein the immunogenic composition is administered as an aerosol or nasal spray. 
     
     
         19 . The immunogenic composition according to  claim 14 , wherein the staphylococcal infection is caused by a staphylococcal species selected from the group consisting of:  S. epidermidis, S. aureus, S. hominis, S. haemolyticus, S. wameri, S. capitis, S. saccharolyticus, S. auricularis, S. simulans, S. saprophyticus, S. xylosus, S. hyicus, S. caprae, S. gallinarum , and  S. intermedius.    
     
     
         20 . The immunogenic composition according to  claim 14 , wherein the animal subject is human, caprine or bovine.